Novo Nordisk Beat Expectations in Q4 and a Huge Catalyst Could Be Coming Soon
In the GLP-1 weight loss market, it's largely been a two-horse race between Eli Lilly and Novo Nordisk (NYSE: NVO). The two ...
Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript
Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over ...
The Motley Fool12d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other perks.
Levi & Korsinsky Notifies Novo Nordisk A/S Investors of a Class Action Lawsuit and Upcoming Deadline – NVO
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn ...
AOL9d
Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price
Novo Nordisk ... CEO of Novo Nordisk, leading based on the company's values. He continued to set clear strategic direction, collaborated effectively with the Board, his team, and the broader ...
Reuters11d
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
In 2023, Maggie's coverage of Danish drugmaker Novo Nordisk and its race to increase production of its new weight-loss drug helped the Health & Pharma team win a Reuters Journalists of the Year ...